Recognition of extraordinary loss (impairment loss)
株式会社PRISM Bio Lab (the Company)
Equipment newly installed during the second quarter accounting period of the fiscal year ending September 2026 (specific name: Not disclosed)
This resulted from capital investment to expand the research and development functions and was attributable to proactive upfront investment necessary to expand the in-house development and joint development businesses.
¥24.290 million (extraordinary loss and impairment loss). The cumulative amount for the interim period was ¥41.804 million (extraordinary loss and impairment loss).
The second quarter accounting period of the fiscal year ending September 2026 (1 January 2026 to 31 March 2026). The cumulative interim period was 1 October 2025 to 31 March 2026.
| Item | Details |
|---|---|
| Event name | Recognition of extraordinary loss (impairment loss) |
| Subject Entity | 株式会社PRISM Bio Lab (the Company) |
| Target Locations / Products | Equipment newly installed during the second quarter accounting period of the fiscal year ending September 2026 (specific name: Not disclosed) |
| Cause | This resulted from capital investment to expand the research and development functions and was attributable to proactive upfront investment necessary to expand the in-house development and joint development businesses. |
| Amount of Impact on Business Performance | ¥24.290 million (extraordinary loss and impairment loss). The cumulative amount for the interim period was ¥41.804 million (extraordinary loss and impairment loss). |
| Accounting period in which recognized | The second quarter accounting period of the fiscal year ending September 2026 (1 January 2026 to 31 March 2026). The cumulative interim period was 1 October 2025 to 31 March 2026. |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This resulted from capital investment to expand the research and development functions and was attributable to proactive upfront investment necessary to expand the in-house development and joint development businesses.